Magnesium sulfate (DrugBank: Magnesium sulfate, Magnesium, Sulfate)
17 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 0 |
11 | Myasthenia | 1 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
46 | Malignant rheumatoid arthritis | 0 |
51 | Scleroderma | 0 |
64 | Thrombotic thrombocytopenic purpura | 1 |
70 | Spinal stenosis | 1 |
93 | Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)] | 0 |
97 | Ulcerative colitis | 0 |
166 | Pseudoxanthoma elasticum | 0 |
225 | Congenital nephrogenic diabetes insipidus | 0 |
235 | Hypoparathyroidism | 0 |
284 | Diamond-Blackfan anemia | 0 |
291 | Hirschsprung disease, entire colon type | 0 |
296 | Biliary atresia | 1 |
297 | Alagille syndrome | 1 |
298 | Hereditary pancreatitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR1800017696 | 2016-07-01 | 2018-08-10 | Effect of Magnesium Sulfate on Muscle Strength in Patients with Myasthenia Gravis | Effect of Magnesium Sulfate on Muscle Strength in Patients with Myasthenia Gravis | Myasthenia Gravis | Group A:Magnesium Sulfate;Group B:Normal saline; | The University of Hong Kong-Shenzhen Hospital | NULL | Recruiting | 18 | 60 | Both | Group A:30;Group B:30; | China |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03237819 (ClinicalTrials.gov) | December 2017 | 13/6/2017 | Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care | Interest of Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care: Multicentric Randomized Controlled Trial | Thrombotic Thrombocytopenic Purpura | Drug: Sulfate, Magnesium;Drug: Placebo - Concentrate | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | N/A | All | 74 | Phase 3 | France |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04391855 (ClinicalTrials.gov) | May 10, 2020 | 13/5/2020 | Wound Infiltration With Tramadol, Dexmedetomidine, or Magnesium Plus Ropivacaine for Pain Relief After Spine Surgery | Effect of Wound Infiltration With Tramadol, Dexmedetomidine, or Magnesium Sulfate as Adjuncts to the Local Anesthetic on Pain Relief After Spine Surgery | Analgesia;Pain, Postoperative;Spinal Stenosis;Spinal Disease | Drug: Tramadol with ropivacaine;Drug: Dexmedetomidine with ropivacaine;Drug: Magnesium with ropivacaine;Drug: Ropivacaine plus normal saline | Aristotle University Of Thessaloniki | NULL | Recruiting | 18 Years | 80 Years | All | 78 | Phase 4 | Greece |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00007033 (ClinicalTrials.gov) | October 2000 | 6/12/2000 | Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease | Alagille Syndrome;Cholestasis;Biliary Atresia | Drug: magnesium gluconate;Drug: magnesium sulfate | National Center for Research Resources (NCRR) | Children's Hospital Medical Center, Cincinnati | Completed | 3 Years | 18 Years | Both | 25 | N/A | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00007033 (ClinicalTrials.gov) | October 2000 | 6/12/2000 | Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease | Alagille Syndrome;Cholestasis;Biliary Atresia | Drug: magnesium gluconate;Drug: magnesium sulfate | National Center for Research Resources (NCRR) | Children's Hospital Medical Center, Cincinnati | Completed | 3 Years | 18 Years | Both | 25 | N/A | United States |